Close Cookie Popup
Cookie Preferences
By clicking “Accept All”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our marketing efforts as outlined in our cookie policy.
Strictly Necessary (Always Active)
Cookies required to enable basic website functionality.
Cookies helping us understand how this website performs, how visitors interact with the site, and whether there may be technical issues.
Cookies used to deliver advertising that is more relevant to you and your interests.
Cookies allowing the website to remember choices you make (such as your user name, language, or the region you are in).

Ventures

Invest in breakthrough healthtech solutions that transform patients' lives.

00:00
/
00:00
00:00
/
00:00
Invest in transformative health innovations
Invest in transformative health innovations

We vet over 1500 innovations yearly and identify, build, and invest in 20 to 25 ventures that address crucial, unmet needs in the healthcare sector. Our ventures lead in areas such as personalized medicine, AI diagnostics, and medical devices, all of which show substantial potential for growth, return, and impact.

00:00
/
00:00
00:00
/
00:00
Invest alongside NLC
Invest alongside NLC

As an investor in an NLC venture, you always invest alongside NLC. Our team of 80+ experts offers comprehensive support to our ventures, including regulatory guidance, product development assistance, and clinical trial setup. This extensive, tailored support system de-risks your investment and enhances the likelihood of venture success. Single-company investments start at €25K.

00:00
/
00:00
00:00
/
00:00
Invest with impact
Invest with impact

By investing in one of our ventures, you help bring transformative health solutions to patients in need, directly impacting their lives. NLC is a certified B Corp and supports UN Sustainable Development Goals 3, 9, and 17, our funds are SDFR-9 compliant, which means we adhere to the strictest impact regulations. Investing in NLC ventures can be your pathway to high-impact capital deployment.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.

a highlight from our portfolio

Angiogenesis Analytics

Angiogenesis Analytics

Angiogenesis Analytics is transforming prostate cancer diagnosis by integrating artificial intelligence with advanced ultrasound technology. Our mission is to make the detection of prostate cancer quicker, more affordable, and significantly less invasive than traditional methods. By pioneering the innovative PCAVision technology, we are setting new standards in healthcare.
Visit website
Download documents
PEP Health

PEP Health

PEP Health is revolutionizing how healthcare providers understand and improve patient experiences by leveraging machine-learning technology to give healthcare organizations, regulators, and insurers the real-time, actionable insights they need to have a direct and dramatic impact on patient experiences.
Visit website
Download documents
NC Biomatrix
Regeneration of intervertebral disc as treatment for low back pain

NC Biomatrix offers a solution for treating chronic back pain caused by intervertebral disc degeneration. Current treatments only address symptoms, have limited effectiveness and often come with complications. NC Biomatrix introduces a new approach using a bio-inductive protein extract obtained from porcine notochordal biomatrix. This injectable treatment addresses the underlying pathology and aims to restore the degenerated disc as a way to definitively treat chronic back pain.

Active
🇳🇱 Netherlands
NC Biomatrix
Crainio
Advancing brain health with a non-invasive pressure monitor for traumatic injuries

Crainio pioneers intracranial pressure (ICP) monitoring, for assessing traumatic brain injuries (TBI) without invasive procedures. Traditional methods involve drilling into the skull, posing risks. Crainio's method uses a forehead probe and a technique called photoplethysmography to measure pulse signals. This gives real-time estimates of ICP without invasive procedures. With TBI being a leading cause of death and disability, Crainio's innovation will potentially revolutionize TBI management.

Active
🇬🇧 United Kingdom
Crainio
Porous Gmbh
Assessing cortical bone health with ultrasound

Porous GmbH has developed an ultrasound technology that accurately diagnoses cortical bone health, addressing the limitations of traditional methods. Osteoporosis affects millions globally, leading to frequent and costly fractures. Current diagnostics often miss early-stage bone deterioration, but Porous GmbH’s patented algorithms allow ultrasound to measure bone quality at a microscopic level for a safer and more precise method for early detection of osteoporosis, also reducing healthcare costs.

Active
🇩🇪 Germany
Porous Gmbh
NeurOdys Therapeutics
Developing treatments to slow or reverse Alzheimer's disease

With over 50 million people living with Alzheimer's and numbers expected to triple by 2050, there's an urgent need for effective treatments. Alzheimer's is a leading cause of death and imposes a global economic burden of $1 trillion annually. Our novel DYRK1A inhibitor aims to slow or even reverse Alzheimer's progression by targeting key pathways with high specificity and effective blood-brain barrier penetration. This innovative small molecule offers superior disease-modifying potential, addressing current treatment limitations and providing new hope for patients and healthcare systems worldwide.

Active
🇳🇱 Netherlands
NeurOdys Therapeutics
Aerion Bioscience
Pioneering early lung cancer screening and saving lives

The challenge with lung cancer lies in its late detection, often leading to unfortunate outcomes. Current screening methods like low-dose CT scans are costly and have radiation risks, while blood tests lack accuracy or are too expensive. Our solution offers a non-invasive blood test that detects lung cancer early with high sensitivity and specificity. This test, with its multi-protein panel, can identify even stage I cancer, improving survival rates and reducing unnecessary procedures.

Active
🇱🇺 Luxembourg
Aerion Bioscience
Altach
Off-the-shelf solution for improved cartilage repair

Altach is tackling the challenge of treating damaged cartilage effectively without costly or complex procedures. Altach's solution is a simple, ready-to-use implant that makes microfracture treatment better. It's made from cartilage-like material and helps the body build new, healthy cartilage. This means fewer surgeries and better outcomes for patients.

Active
🇮🇪 Ireland
Altach
Theragenix
Bone repair technology using gene therapy during surgery

TherageniX introduces an approach to improve bone implants by augmenting autologous bone grafts with regenerative gene therapies. Traditional bone repair methods face challenges like rejection, infection, and limited regenerative capacity. TherageniX's solution aims to enhance the regenerative bone grafts, improving functional outcomes and reducing donor trauma. This method bypasses regulatory and manufacturing hurdles, offering a promising advancement in bone grafting procedures.

Active
🇬🇧 United Kingdom
Theragenix
MIR Therapeutics
Gene therapy for lasting and potent seizure control in drug resistant epilepsy patients

Epilepsy causes uncontrolled seizures, greatly reducing quality of life and sometimes leading to early death. Over 50 million people worldwide have epilepsy, but only two-thirds respond to medication. For those with drug-resistant epilepsy, treatment options are limited and often ineffective. MIR Therapeutics is developing a new gene therapy to provide lasting and powerful seizure control for drug-resistant epilepsy patients. Their therapy delivers microRNA-335 to the affected brain regions using an AAV9 viral vector, which helps control hyperexcitability by regulating voltage-gated sodium channels. This results in fewer and less severe seizures.

Active
🇳🇱 Netherlands
MIR Therapeutics

Our impact

14
Countries active in
20-25
Ventures built annually
247K
Patients impacted
70+
Active ventures in our portfolio
80+
Healthcare experts
€135M+
Raised by NLC ventures

Explore our 2023 Impact report

Woman with hands in the air in nature
Maurits Schouten
00:00
/
00:00
I consider the medical sector to be very attractive. However, without the right expertise, network, and diversification, the risks can be significant. NLC removes these barriers and creates an attractive opportunity for me to participate as an investor in this sector.
Maurits Schouten

Maurits Schouten

Impact investor and Board Member of PYM

Peter Veldman
00:00
/
00:00
What I really like about NLC and what triggered my investment in the company is the strong culture and the quality of the team. NLC is able to de-risk the innovation cycle by building ventures at scale, thereby playing a leading role in shaping the future of healthcare.
Peter Veldman

Peter Veldman

Advisor and previous Deputy Head of Fund Operations at EQT Group

Invest in a portfolio of companies

A formal clothed man on a bridge in the city

Create a healthier future with us

Nina Rijnders
Investor Relations